RxDoctor Payments Data

Trisha Halderman

Acute Care · Liberty Township, OHNPI 1649822461

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,943 of the $4,120 with a category attached, or 71.4%. 11 manufacturers reported payments, led by Boston Scientific at 39.5% of the total. Reporting peaked in 2023 at $1,992 and has fallen 61.8% since, to $762 in 2025. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,120in general payments, 2019–2025

Across 33 payments — averaging $124.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • E.r. Squibb & Sons, L.L.C.$617
  • AstraZeneca$575
  • Boehringer Ingelheim$488
  • Bayer$143
  • Esperion Therapeutics, Inc.$125
  • plus $542 from 5 others

What the payments were for

  • Travel & lodging$1,17629%
  • Food & beverage$2,94371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,120 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$69,005
Medicare patients
494
Services billed
698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$167,013
EntrestoSacubitril/Valsartan117$114,134
JardianceEmpagliflozin60$69,343
FarxigaDapagliflozin Propanediol20$25,941
XareltoRivaroxaban11$16,446
Metoprolol Succinate185$2,096
Rosuvastatin Calcium98$1,458
Ranolazine ErRanolazine20$1,173
Atorvastatin Calcium138$1,047
Isosorbide Mononitrate ErIsosorbide Mononitrate80$875
Torsemide63$860
Carvedilol130$834
Amiodarone Hcl27$720
Ezetimibe31$638
Losartan Potassium75$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$488$69,34360 claims
AstraZenecaFarxiga$575$25,94120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.

Other acute care in Liberty Township

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →